1981 Volume 55 Issue 2 Pages 116-123
Cefopepazone (CPZ) is a newly developed antibiotic of the cephalosporin group. It has a greater antibacterial activity than any already known antibiotic of the cephalosporin group against Pseudomonas aeruginosa, Enterobacter and indole (+) Proteus. Its concentration in blood shows a half-life period which is as long as about 120 minutes. In view of these advantages, we have made clinical studies on the low dosage therapy of the medicine.
We have administered 1 g of this medicine per day for 44 clinical cases. Although they includes several mild cases of infection, the medication turned out to be effective for as much as 88.6% of the cases. More specifically, the medicine was found excellent for 17 cases, good for 22 cases and fair for two cases, while it was poor for only three cases. The medicine was also effective to four of the five cases for which another known antibiotic had turned out to be ineffective.
As regards the bacteriological effect of the medicine, it caused 15 of the 20 inflaming strains initially detected, or 75.0% of them to disappear.
No single case was encountered with any side effect, or any abnormal result of laboratory findings, but the medicine was considered to ensure a high degree of safety in use.
In view of the foregoing results, 1 g of CPZ per day would be sufficient for effective treatment of mild and moderate cases of infection.
